Key terms
About AFMD
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AFMD news
Apr 04
11:03am ET
Biotech Alert: Searches spiking for these stocks today
Apr 01
7:26am ET
Affimed price target raised to $5 from $1 at Stifel
Apr 01
7:19am ET
Truist Financial Sticks to Its Buy Rating for Affimed (AFMD)
Apr 01
6:26am ET
Promising Clinical Trials and Strategic Financial Management Affirm Buy Rating for Affimed
Apr 01
6:22am ET
Affimed price target raised to $10 from $5 at H.C. Wainwright
Mar 31
10:20pm ET
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)
Mar 31
4:12pm ET
Affimed price target lowered to $25 from $30 at Wells Fargo
Mar 31
11:05am ET
Buy Rating Affirmed on Affimed: Promising Clinical Outlook and Robust Financial Position
Mar 28
9:27pm ET
Affimed Therapeutics’ Optimistic Clinical Outlook
Mar 08
7:50pm ET
Affimed NV trading halted, news pending
Mar 06
6:33am ET
Affimed announces 1-for-10 reverse stock split
Jan 08
4:16pm ET
Affimed provides update on AFM24-102 Trial in EGFR-wildtype NSCLC
Jan 08
8:19am ET
Affimed announces strategic restructuring, reducing headcount by 50%
Jan 08
8:18am ET
Affimed CEO Adi Hoess to step down
No recent press releases are available for AFMD
AFMD Financials
Key terms
Ad Feedback
AFMD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AFMD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range